BSIC | Bocconi Students Investment Club
  • Articles
    • Markets
    • Corporate Finance
  • The Team
    • Members
    • Alumni
  • About Us
  • Gallery
  • Join Us
  • Contacts
  • Subscribe
  • Collaborations

Humira

Corporate Finance Debt Deals Equity Deals M&A Deals Old Articles

Teva and Mylan : The Plot Thickens…

Teva Pharmaceutical Industries ; Market Cap (as of 25/04/2015): $62,67bn Mylan Pharmaceuticals ; Market Cap (as of 25/04/2015): $36,06bn   Introduction In the healthcare industry, the saying “eat or be eaten” no longer applies. Instead, the adage of “make a bid or wait for an offer” would be more appropriate Read more…

By BSIC, 10 years25 April 2015 ago
Corporate Finance Debt Deals Equity Deals M&A Deals Old Articles

AbbVie’s back on track, but at what price?

AbbVie Inc.; market cap (as of 06/03/2015): $88.7bn Pharmacyclics Inc.; market cap (as of 06/03/2015): $19.3bn Introduction On March 4, the pharmaceutical company AbbVie, outbidding the competitor Johnson & Johnson, agreed to buy the cancer biotech company Pharmacyclics in a $21bn transaction. The Chicago based company will pay $261.25 per Read more…

By BSIC, 10 years7 March 2015 ago
Corporate Finance Equity Deals M&A Deals Old Articles

Is there more than tax-inversion to AbbVie-Shire $54bn deal?

AbbVie Inc., Market Cap (as of 19/09/2014): $94.63bn Shire plc., Market Cap (as of 19/09/2014): £31.12bn In its attempt to become one of the global leaders in the rare diseases market, AbbVie successfully got the approval from Shire’s board of directors for its $54bn acquisition. This approval came after two Read more…

By BSIC, 11 years20 September 2014 ago

[instagram-feed]

Follow Us

  • Disclaimer
  • About Us
  • Join Us
  • Contacts
  • Subscribe
  • Privacy Policy
  • Cookie Policy
Hestia | Developed by ThemeIsle